Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B

Table 1

Baseline clinical characteristics of ETV monotherapy hepatitis B patients.

Characteristics	ETV monotherapy (n = 130)
Age at the beginning (years, (median, IQR))	62.0 (51.0–71.3)
Gender (M/F (n, %))	72 (55.4)/58 (44.6)
Baseline AST (U/L (median, IQR))	37.0 (23.8–75.5)
Baseline ALT (U/L (median, IQR))	37.5 (22.0–95.5)
Prior NA exposure (yes/no (n, %))	22 (16.9)/108 (83.1)
Baseline HBeAg (+/−/unknown (n, %))	51 (39.2)/65 (50.0)/14 (10.8)
Baseline HBV DNA (LogC/mL (median, IQR))	5.1 (2.5–7.7)
Baseline HBcrAg (LogU/mL (median, IQR))	5.1 (3.0–6.8)
Genotype (A/B/C/D/unknown (n, %))	4 (3.1)/14 (10.8)/70 (53.8)/1 (0.8)/41 (31.5)
Fibrosis stage (F1/F2/F3/F4/unknown (n, %))	7 (5.4)/27 (20.8)/12 (9.2)/3 (2.3)/81 (62.3)
Response to the therapy (resistant/effective/excluded (n, %))	15 (11.5)/97 (74.6)/18 (13.8)